<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399747</url>
  </required_header>
  <id_info>
    <org_study_id>Asan_LMP2017-002</org_study_id>
    <nct_id>NCT03399747</nct_id>
  </id_info>
  <brief_title>Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 Study of Abbreviated 3 Cycles of Rituximab plus CHOP (Cyclophosphamide, Adriamycin,&#xD;
      Vincristine, and Prednisolone) Immunochemotherapy in Patients with Completely Excised&#xD;
      Localized Gastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma(SATURDAY STUDY)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 7, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>6 to 8 weeks after completion of the 3rd cycle of treatment(each cycle is 28days)</time_frame>
    <description>CT(Computed tomography) / PET-CT(Positron emission computed tomography)/ Colonoscopy(if necessary) by Lugano stage I or II1, Paris stage T1-2NO-1MO</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess response rate</measure>
    <time_frame>after completion of the treatment, up to 2years</time_frame>
    <description>CT/ PET-CT/Colonoscopy(if necessary) by Lugano stage I or II1, Paris stage T1-2NO-1MO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess response rate</measure>
    <time_frame>after completion of the treatment, up to 4years</time_frame>
    <description>CT/ PET-CT/Colonoscopy(if necessary) by Lugano stage I or II1, Paris stage T1-2NO-1MO</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess overall survival</measure>
    <time_frame>after completion of the treatment, up to 5years</time_frame>
    <description>CT/ PET-CT/Colonoscopy(if necessary) by Lugano stage I or II1, Paris stage T1-2NO-1MO</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Abb-R-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abb-R-CHOP</intervention_name>
    <description>Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma&#xD;
3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy</description>
    <arm_group_label>Abb-R-CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Completely Excised LocalizedGastrointestinal CD20 (+) DLBCL(Diffuse Large B-cell&#xD;
             Lymphoma )&#xD;
&#xD;
          -  CD 20, CD5, CD10, MUM-1, BCL-6, BCL-2, Ki-76, EBV(Epstein-Barr virus )positive&#xD;
&#xD;
          -  Lugano Criteria: Stage I, II1&#xD;
&#xD;
          -  Paris Criteria: T1-2NO-1MO&#xD;
&#xD;
          -  Stage-adjusted International Prognostic Index: 0-1&#xD;
&#xD;
          -  A patient who has not previously received chemotherapy or radiation treatment for the&#xD;
             DLBCL&#xD;
&#xD;
          -  ECOG(Eastern Cooperative Oncology Group ) :0-2&#xD;
&#xD;
          -  In case of patients who do not have any residual lesion due to complete surgical&#xD;
             removal of lymphoma I. A patient who has been confirmed to have no residual lesion in&#xD;
             the CT conducted following surgery or Ii. Preoperative imaging confirmed as the first&#xD;
             phase of a single lesion and post-operative lesion finding that the patient has been&#xD;
             confirmed with&#xD;
&#xD;
          -  In case of a 50 % or higher cardiac output when there is no clinically significant&#xD;
             abnormality in MUGA(multiple gated acquisition scan) or deep frequency&#xD;
&#xD;
          -  If appropriate renal function (below serum creatinine 2.0 mg dL or an estimated&#xD;
             glomerule filtration rate of 40 mL / mill1.73m2 or higher)&#xD;
&#xD;
          -  If the appropriate liver function is present (serum bilirubin), less than three times&#xD;
             the normal upper limit of AST(aspartate aminotransferase ) (non-hepatic) unless the&#xD;
             serubin is caused by Gilbert syndrome or originated from a non-hepatic ;&#xD;
&#xD;
          -  Proper Bone marrow function (ANC-1500mm 3 or higher, number of platelets &gt; 755mm3, and&#xD;
             hemoglobin 9.0 g/L or higher) If the screening in the CS(cerebrospinal fluid)F is not&#xD;
             acceptable, the dose is given in - 7&#xD;
&#xD;
          -  For males, blocking contraceptive methods such as condoms are required at least 6&#xD;
             months from the date of the last administration of the cancer and such measures are&#xD;
             agreed&#xD;
&#xD;
          -  For fertile women, it must be agreed to apply contraceptive measures (oral&#xD;
             contraceptive pills, in the womb, blocking contraceptive methods, etc.) for at least 6&#xD;
             months from the date of administration of the last cancer.&#xD;
&#xD;
          -  decided to participate in this study voluntarily and agree in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV or HCV(hepatitis C virus) positive patient. However, HBVhepatitis B virus)&#xD;
             positive patients using anti-viral therapy are allowed&#xD;
&#xD;
          -  Patient with current history of other cancers (e.g. cervical carcinoma in situ,&#xD;
             treated basal cell carcinoma, early cancer, excluded from the present condition of&#xD;
             cancer.&#xD;
&#xD;
          -  pregnant or nursing woman, male or female who do not agree with appropriate&#xD;
             contraception.&#xD;
&#xD;
          -  Systemic disease that is inappropriate for administration of anticancer drugs I. A&#xD;
             patient who within the past 6 months had a clinically significant heart attack&#xD;
             (non-medical congestive heart failure, symptomatic coronary artery disease, severe&#xD;
             myocardial infarction) or Ii. Serious neurology and psychiatric disease Iii. Serious&#xD;
             activity infection Iv. Other medical conditions that are difficult to perform in&#xD;
             clinical trials&#xD;
&#xD;
          -  If you are allergic to chemicals used in this study&#xD;
&#xD;
          -  Patients who receive another test medication during a clinical trial or who is&#xD;
             administered both chemotherapy, hormone therapy and immunization&#xD;
&#xD;
          -  Patient with Bulky disease (length of diaphragm 10 cm)&#xD;
&#xD;
          -  Patient who is unsuitable for participation in a clinical examination according to the&#xD;
             judgment of a researcher&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>December 25, 2017</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Cheolwon Suh</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

